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Successful primary closure of classic bladder exstrophy (BE) is crucial for development
of bladder capacity and voided continence. It is universally agreed that an intensive pain
management including the use of caudal epidural anesthesia is an essential cornerstone
for the outcome of this complex surgery. Whether and to what extent pain is caused
by structural or functional changes is not yet known. The nerve growth factor (NGF)
is regarded as a marker for pain in different bladder disorders. This prospective study
investigated the role of histological alterations and NGF in patients with BE including
34 patients with BE and 6 patients with congenital vesicoureterorenal reflux (VUR) who
served as controls. Between January 2015 and April 2020 transmural bladder biopsies
were taken from the posterior bladder wall during delayed primary bladder closure. The
samples were stained for histological evaluation and subjected to immunohistochemistry
to analyze NGFR p75. Differences in histological alterations were examined with Fisher’s
exact test, and Mann-Whitney-U-test was used to compare the NGFR p75 staining
intensity between patients with BE and controls. Patients with BE showed significantly
more often acute inflammation (p < 0.001), squamous metaplasia (p = 0.002), and
cystitis glandularis (p = 0.005) as well as NGFR p75 in the urothelium (p = 0.003) than
patients with VUR. A limitation of this study is the small number of participants due to the
rare disease entity. Similar to other painful bladder disorders, pain transmission in BE after
intitial closure may in part be facilitated by elevated NGF signaling through its receptor.
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INTRODUCTION
Successful primary closure is crucial for the development of bladder capacity and voided continence
(1, 2). It is universally agreed that an appropriate peri- and postoperative pain management
including the use of caudal epidural anesthesia is essential for the outcome of this complex
surgery (3–5).
In a majority of unclosed bladders urothelial differentiation changes could be shown (6). These
findings may result in a dysfunctional barrier of the urothelium with implications for the structural
and functional properties of the unclosed bladder wall.
Promm et al. NGF Bladder Exstrophy
In the past decades, biomarkers have become the focus of
investigations for the presence and progression of painful bladder
conditions (7, 8). Several studies on urinary bladder disorders
such as overactive bladder, interstitial cystitis, or neurogenic
bladder have already indicated the crucial role of the nerve
growth factor (NGF) in this context which has been verified
by elevated NGF-levels either in the urine or in bladder wall
biopsies (7–14). NGF belongs to the neurotrophin family and
is considered to be involved in regulating neural function,
inflammatory processes, as well as pain mechanisms (15). NGF is
produced by the bladder smoothmuscle and the urothelium (13).
In urinary bladders, NGF is assumed to mostly affect afferent
fibers. NGF also seems to play a significant role in abnormal
afferent signaling and in increased bladder sensations (12, 13).
NGF can activate two specific receptors: the tyrosine kinase
receptor A (Trk-A) and the p75 neurotrophin receptor (NGFR
p75). NGFR p75, which is present in many different types of
bladder cells, is well-established in animal models and also used
in clinical studies (16–18). Whether and to what extent peri- and
postoperative pain might be caused by structural or functional
changes in the exstrophic bladder wall is yet unknown.
Therefore, besides the histological changes, in this study we
want to assess the occurrence and the distribution of low affinity
receptor NGFR p75 in the bladder wall of unclosed BE.
MATERIALS AND METHODS
Transmural bladder biopsies were prospectively obtained from
patients with BE who underwent primary bladder closure in the
6–8 week of life in a single institution between January 2015 and
April 2020. Only patients with classic BE were included in this
investigation. Cloacal exstrophies, exstrophy variants, isolated
epispadias or redo-cases were excluded (Figure 1). The biopsies
from the bladder wall contained urothelium, submucosa, and
detrusor muscle. Bladder biopsies from patients with congenital
VUR taken during the same time period served as controls, as
primary VUR is not associated with any major alterations of the
urothelium and also not known for causing bladder pain (19).
Only six parents had given their consent for this procedure. The
biopsies were obtained during open bladder surgery.
Collection and histological as well as immunohistochemical
examination were approved by the Ethics Committee of the
University of Regensburg. Written informed consent was given
by the parents.
Histological Assessment
The samples were fixed in 4% formalin and sent to the laboratory.
There, the tissues were embedded in paraffin and stained with
hematoxylin and eosin (HE) for histological assessment by
an expert uropathologist (FW). All tissues were anonymized
and analyzed microscopically (Leitz DM RBE light microscope,
Abbreviations: BE, classic bladder exstrophy; BOO, bladder outlet obstruction;
HE, hematoxylin and eosin; KC, ketamine cystitis; IC, interstitial cystitis; NB,
neurogenic bladder dysfunction; NDMA, N-methyl-D-aspartate receptors; NGF,
nerve growth factor; NGFR p75, low affinity nerve growth factor receptor
p75; OAB, overactive bladder; STD, standard deviation; Trk-A, tyrosine kinase
receptor A; VUR, vesicoureterorenal reflux.
FIGURE 1 | Flow-chart of patients.
Leica, Germany) for inflammatory infiltrates, acute and chronic
inflammation, suburethelial fibrosis, squamous metaplasia, as
well as cystitis glandularis and cystitis cystica.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue blocks were
sectioned at 4µm and mounted onto poly-L-lysine-coated
slides. Immunohistochemical incubation was carried out in a
BenchMark IHC Full System immunostainer (RocheDiagnostics,
Mannheim, Germany) using the avidin-biotin peroxidase
method with diaminobenzidine as chromogen according to
the manufacturer’s instructions (UltraView DAB Detection Kit,
Firma Roche Diagnostics, Mannheim, Germany). Anti-NGFR
p75 (rabbit polyclonal, Sigma, Germany) was used as primary
antibody at a dilution of 1:400. Anonymized sections were
independently evaluated semiquantitatively in a light microscope
by a neuroanatomist (WN) (Leica Aristoplan, Leica, Bensheim,
Germany) and a pediatric urologist (MP) (Zeiss Lab A1, Zeiss,
Jena, Germany) who were both blinded to the patients’ history.
Density of NGFR p75 was assessed from absent, sparse, moderate
dense, to dense.
Statistical Analysis
Statistical analysis was done using the software package SPSS
(Version 25, SPSS Inc, Chicago, Illinois). The level of significance
was set at p ≤ 0.05 for all tests. Because data analyses were
of exploratory manner, no adjustments for multiple testing
were conducted.
Descriptive analyses were done using frequency (n),
percentage (%), mean (m), standard deviation (SD), median
(med), and first as well as third quartiles (IQR). Fisher-Exact tests
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TABLE 1 | Histopathological findings in bladder specimens from patients with bladder exstrophy (BE) obtained during primary closure and from patients with congenital













patients with BE 29 (85) 33 (97) 25 (74) 29 (85) 13 (38) 22 (65)
patients with VUR 0 (0) 6 (100) 5 (83) 1 (17) 0 (0) 0 (0)
p-value <0.001 1.000 1.000 0.002 0.152 0.005
Frequency and percentage in brackets of patients with histopathological findings are presented. Statically significant p-values of Fisher’s exact tests in bold.
were used to compare the two patient groups for each feature of
the histopathological findings. Mann-Whitney-U-test was used
to compare NGFR p75 between the two patient groups.
RESULTS
Patient Data
The biopsies were prospectively obtained from 34 patients (20
boys/14 girls) with BE who underwent primary bladder closure
between January 2015 and April 2020.Mean age at surgery was 61
days (SD 23.9 days, min = 38, max = 169). As controls, bladder
biopsies from six children (two boys/four girls) with high-grade
VUR were used. Mean age at surgery was 412 days (SD 292.4
days, min = 8, max = 822). Biopsies were taken during creating
an incontinent vesicocutaneostomy and open anti-reflux plasty.
Histological Analysis
We compared the histopathological changes in the bladder
biopsies obtained from patients with BE during primary bladder
closure and from patients with VUR during reflux surgery
(Table 1). Acute inflammation (p < 0.001), squamous metaplasia
(p = 0.002), as well as cystitis glandularis (p = 0.005) (Figure 2)
were more frequently diagnosed in patients with BE than in
patients with VUR. The two patient groups did not significantly
differ in the incidence of chronic inflammation, suburethelial
fibrosis, and cystitis cystica (p-value >0.05).
Immunohistochemical Analysis
Immunostaining for NGFR p75 in the urothelium and bladder
stroma/detrusor was compared between patients with BE and
patients with VUR. Table 2 summarizes the observations of
NGFR p75. Patients with BE had a significantly higher density of
NGFR p75 in the urothelium than patients with VUR (p= 0.003).
The density of NGFR p75 in the bladder stroma/detrusor did not
significantly differ between the two patient groups (p = 0.425).
However, patients with BE tended to have a higher density of
NGRF p75 in this area.
In the detrusor, NGFR-positive axon bundles were typically
seen in the adventitia of blood vessels. Immunostaining was
most pronounced in the perineurium in all patients, whereas
nerve fibers sometimes showed less intense staining. At light
microscopy resolution, it was impossible to determine if Schwann
cells or axons or both were stained (Figure 3).
In the urothelium, NGFR p75 immunoreactivity was almost
exclusively confined to the basal cell layer. Only occasionally
FIGURE 2 | Histological assessments of bladder specimens of infants taken at
primary delayed closure (Hematoxylin-eosin stained). (A) Typical alteration of
cystitis glandularis et cystica (5× magnification). (B) Cystitis glandularis with
squamous metaplastia and acute erosive inflammation as well as fibrosis
(10× magnification).
was filamentous staining detected in the transitional layer that
eventually reached the luminal layer (Figure 4).
DISCUSSION
Initial bladder closure in BE patients still remains a challenge.
Patients undergoing this complex surgery depend on a
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TABLE 2 | Observation of NGFR p75 in the urothelium and detrusor in biopsies from patients with bladder exstrophy (BE) obtained during primary closure and from
patients with congenital vesicoureterorenal reflux (VUR) obtained during reflux surgery who served as controls.
NGFR p75
Absent Sparse Moderate dense Dense p-value
Urothelium Patients with BE 1 (3) 12 (35) 12 (35) 9 (26) 0.003
Patients with VUR 4 (67) 1 (17) 1 (17) 0 (0)
Detrusor Patients with BE 0 (0) 10 (29) 15 (44) 9 (26) 0.425
Patients with VUR 0 (0) 2 (33) 4 (67) 0 (0)
Frequency and percentage in brackets are presented. Statically significant p-values of Mann-Whitney-U-tests in bold.
multimodal pain management to ensure well-being and a
successful outcome. Painful bladder disorders in other conditions
(e.g., mucosal inflammation, interstitial cystits) are characterized
by an increase in NGF and its low-affinity receptor NGFR p75
(9–12, 14). In this study we looked on the occurrence of NGFR
p75 and histological alterations in 34 patients with BE presenting
for delayed primary closure and six patients with VUR who
served as controls. The two groups significantly differed with
regard to acute inflammation (p < 0.001), squamous metaplasia
(p = 0.002), and cystitis glandularis (p = 0.005) as well as for
NGFR p75 immunostaining in the urothelium (p= 0.003).
Except for chronic inflammation and subepithelial fibrosis, the
histological results of this study are comparable to the findings of
Rubenwolf et al. who analyzed 29 patients with BE presenting for
delayed primary closure (6). The two alterationsmay be similar in
both groups due to inflammatory processes over a certain period
of time. The high rate of acute inflammation and morphological
changes may be related to exposure to wound dressing before
bladder closure or to intrauterine amniotic fluid during exposure
(6, 20). In context with bladder extrophy cystitis cystica is
commonly considered as benign, whereas cystitis glandularis
is discussed to have a malignant potential, but so far there is
no ultimate evidence to suggest that this alteration is per se
premalignant. (6, 21–23).
In the following sections, the role of NGF in inflammation will
be discussed.
Only a few studies have immunohistochemically evaluated
NGF or its low-affinity receptor p75 in bladder wall biopsies of
patients with painful or irritative bladder disorders.
In 1997, Lowe et al. (12) showed increased NGF levels in
12 women with bladder conditions due to idiopathic sensory
urgency, chronic cystitis, or interstitial cystitis (IC). Two bladder
biopsies of the lateral bladder wall had been obtained from each
patient by means of a transurethral punch. The samples were
histologically graded after staining withHE. The level of NGFwas
assessed with fluorometric ELISA, and NGF-immunostaining
was done by means of indirect immunofluorescence. The level
of NGF was statistical significantly higher in the groups with
bladder disorders than in the control group consisting of
four women with stress incontinence without any irritative
symptoms. Also, in these groups positive immunostaining for
NGF was observed in the transitional epithelium, but not in
the control samples. NGF-immunoreactivity was intense and
present throughout all layers of the epithelium in the women
FIGURE 3 | Specimen of a 54-day old girl with classic bladder exstrophy
undergoing primary closure. Strong NGFR p75 positive axon bundles in the
adventitia of an artery (A) and a vein (V) in the detrusor. Note the strong
perineurial staining of the thicker bundles (arrow).
with idiopathic sensor urgency, whereas the patients with chronic
cystitis showed weaker staining and irregular distribution within
the epithelium. In our study, NGFR p75 immunoreactivity was
almost confined to the basal layer. Furthermore, in contrast to
our observation, Lowe et al. did not report any positive NGF
staining in the submucosal tissue or in muscle layers (12).
In 1998, Vaidyanathan et al. published their results about
the occurrence of the p75 NGF receptor in the urothelium
in 26 adult patients with neuropathic bladders. Two cold
cup biopsies were cystoscopically obtained from the trigonal
area of each patient. One biopsy was referred to routine
histopathological examination, and the other one was
stained immunohistologically for NGFR p75. In all patients,
immunostaining for NGFR p75 was detected in neural structures
and, similar to our results, especially in the basal layer of the
transitional layer. In 12 patients, immunostaining of the luminal
layer showed varying degrees. In many stains, the nerve fibers
in the submucosa ran in a random manner, also reaching very
close to the basal layer, but no intra-epithelial terminals were
seen (14).
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FIGURE 4 | Specimen of a 64-day old girl with classic bladder exstrophy
undergoing primary closure. Strong NGFR p75 positive cells in the basal
urothelium. The arrows mark the thin NGFR p75 positive nerve fiber bundles of
the lamina propria.
In 2013, scientists from York examined tissue samples
obtained cystoscopically either as cold cut biopsies or
from cystectomy specimens of 21 patients with the painful
bladder condition of ketamine cystitis (KC). The tissues were
immunohistochemically labeled for NGFR p75. The findings of
the 21 patients with KC were compared to those of six patients
with idiopathic detrusor overactivity (IDO), four patients with
stress urinary incontinence (SUI), and 11 patients with IC.
NGFR p75 was predominantly detected basally in the samples
of patients with KC, but irregularly also in the samples of patients
with IDO and SUI. Eight of 11 samples of patients with IC did
not show the normal basal pattern but weak punctuate staining
throughout the urothelium. In 16 patients with KC, urothelium
and intermediate cells were retained, and 10 of the 16 samples
showed an expansion of intense basal NGFR p75 expression into
the intermediate cells (24).
There are still many unresolved issues concerning the role
of NGF and its receptor NGFR p75 in the pathophysiology of
bladder disorders. Our results showed a statistically significant
difference in NGFR p75 in the urothelium between patients with
BE and patients with VUR. No statistically significant difference
was found in the submucosal tissue and detrusor but a notable
tendency to higher density.
Increased distribution of NGF or NGFR p 75 in the
urothelium is more often reported in painful bladder disorders,
whereas higher levels of NGF or NGFR p75 have been described
for the submucosal tissue and detrusor in functional bladder
alterations (12–14, 24).
In all our specimens, NGFR p75 in the submucosal
layers including the detrusor was most pronounced in the
perineurium, whereas nerve fibers showed less intense staining.
This finding is consistent with the observation in human
cutaneous nerve fibers in which NGFR p75 mainly occurs
in Schwann cells, particularly in their membrane (25). Abdo
et al. even found specialized cutaneous Schwann cells that
are responsible for initiating pain (26). The distribution of
NGFR p75 on a cellular level based on electron microscope
findings may be helpful to clarify its role in the mechanism of
pain regulation.
Based on numerous experimental and clinical studies,
there is no longer any doubt about the correlation between
NGF and painful sensations or inflammatory processes
(13, 27, 28). As mentioned above, our histological findings
show a significant difference in acute inflammation and cystitis
glandularis between patients with BE and the control group.
Inflammation has been discussed to stimulate NGF production
(13). NGF acts as a mediator inducing clinical symptoms
such as thermal and mechanical hyperalgesia; even a single
systemic injection of NGF induces profound and long-lasting
hyperalgesia (27, 28). Lewin et al. (28) could even demonstrate
that NGF-induced thermal and mechanical hyperalgesia are
mediated by different mechanisms. The rapid onset of thermal
hyperalgesia is due to peripheral mechanisms with mast
cell degranulation, and the late component involves central
N-methyl-D-aspartate receptors (NMDA), whereas NGF-
induced mechanical hyperalgesia seems to be independent of
both (28).
NGF seems to be key factor in painful and functional
bladder disorders. Although no data exist on NGF or its p75
receptor in BE, our results are in line with investigations
showing increased NGF expression of the unclosed bladder
wall in patients with other painful urological disorders (7–13,
24).
Further studies also in closed bladders and including
electron microscopy are necessary to detect the distribution
of NGFR p75 in the bladder wall. Additionally, clinical
trials are of utmost importance to evaluate the relevance
of NGFR p75 and NGF as potential biomarkers in this
rare disease entity. In this context, monitoring of potential
therapeutic approaches such as antimuscarinics or hyaluronic
acid is of particular interest, even in unclosed bladder
templates (29).
This study has some limitations. First, because of the staining
for NGFR p75 used in this study, the results have to be interpreted
carefully when drawing any conclusions on NGF itself. However,
other studies have indicated a correlation between the expression
of NGF and its low-affinity receptor p75 (18, 30).
Second, this study did not assess the level of pain or the
need for analgesics. Therefore, it remains unclear whether
it is the increased level of NGF or its receptor p75 that
actually leads to a higher level of pain in the respective
patient group.
Third, our study only included patients with unclosed
BE undergoing delayed bladder closure. Further studies
should include samples from neonates undergoing immediate
closure as well as from closed bladders to determine possibly
varying presence and distribution patterns of the receptor in
these groups.
Lastly, the small sample size of this study precludes advanced
statistical comparison but represents a comparatively large
sample for this rare disease entity.
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Although there is a number of limitations, we believe that
this study might contribute to possibly identify a potential pain
pathway in this rare entity.
CONCLUSION
This study is the first to assess histological alterations as
well as the occurrence and distribution of NGFR p75 in the
unclosed exstrophic bladder wall. We hypothesize that structural
or functional changes in the exstrophic bladder wall may
contribute to peri- and postoperative pain. This hypothesis can
be supported by a statistically significantly increased occurrence
of acute inflammation as well as a statistically significantly
increased occurrence of NGFR p75 in the urothelium in
patients with unclosed bladder templates compared to patients
with VUR.Nevertheless, our data are not sufficient proof to
clarify the role of these changes regarding this topic. Further
studies, especially in neonatal closures as well as in long
term of closed bladders are crucial to substantiate these first
findings and to evaluate the possible relevance of NGF as
potential biomarkers or potential therapeutic approaches in this
rare entity.
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